A signal from the kidney that regulates red blood cell production — a hormone released when renal tissue senses hypoxia, traveling to the marrow to command red-cell production. It is the reason altitude training raises hematocrit, why chronic kidney disease causes anemia, and why blood doping can alter an athlete's measured red-cell profile.
Chemical Class
Glycoprotein (165 aa)
Source
Kidney (peritubular interstitial cells); liver in fetus
The EPO gene is switched on by HIF-2α, which accumulates in renal interstitial cells whenever oxygen delivery falls — anemia, altitude, hypoxia, carbon monoxide.
Conversely, high oxygen delivery (transfusion, hyperoxia) degrades HIF and silences EPO within hours — pure supply-and-demand control with no higher-axis governor.
Fetal liver makes EPO; after birth the kidney takes over — reduced renal EPO production contributes to CKD anemia, alongside factors such as inflammation and iron restriction.
Nocturnal secretion peaks and exercise both raise it modestly.
Mechanism of Action
EPO binds its receptor on erythroid colony-forming cells, activating JAK2/STAT5, which blocks apoptosis (via BCL-xL) and drives proliferation and hemoglobinization. It supports the survival and maturation of EPO-responsive erythroid progenitors; its effects depend on the stage of development and the availability of other resources.
Physiological Effects
Maintains the resting hematocrit: basal EPO quietly replaces the roughly 1% of red cells retired each day.
Hypoxia adaptation: at altitude, EPO rises within hours and hematocrit climbs over weeks — the acclimatization curve.
Non-erythroid roles, including possible tissue protection in ischemia, have been investigated; their clinical relevance remains uncertain.
Interactions & Feedback
Iron is the co-limiting resource: EPO expands erythropoiesis only if iron is available — hepcidin's iron lockout explains inflammation-driven EPO resistance.
Long negative feedback loop: more red cells → more oxygen delivery → less HIF → less EPO; a loop measured in weeks, not minutes.
Testosterone stimulates EPO — one mechanism of androgen-induced erythrocytosis and doping synergy.
When It Goes Wrong
CKD anemia: EPO deficiency from lost renal mass — the original indication for recombinant EPO (epoetin), dosed to a target hematocrit, not a normal one.
Chemotherapy-associated anemia: epoetin may be used in selected patients; cancer-related anemia has multiple causes, and eligibility depends on the treatment context.
Doping: recombinant EPO and its analogs (darbepoetin) thicken blood and raise thrombotic risk; detected by isoform electrophoresis and the Athlete Biological Passport.